Issues
-
Cover Image
Cover Image
About the Cover
Poor clinical outcome in cancer patients is associated with the presence of cancer-associated fibroblasts (CAFs). However, fibroblasts are heterogenous and can have different functions, and whether CAFs directly interact with and impact T cells in the tumor microenvironment remains to be determined. Cremasco and Astarita et al. show that two populations of FAP+ mesenchymal stromal cells exist in breast cancer tumors from humans and mice: those that express podoplanin (PDPN+ CAFs) and those that do not (cancer-associated pericytes; CAPs). Each population has a distinctive gene signature and localization within tumors, and FAP+PDPN+ CAFs were shown to suppress T cells, whereas FAP+PDPN− CAPs were not immunosuppressive. These data highlight how different FAP+ stromal cell populations can modulate the breast cancer tumor microenvironment. Read more in this issue on page 1472. Original image from Supplementary Fig. S1E. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
What We’re Reading
In the Spotlight
Cancer Immunology at the Crossroads
Cancer Immunology Miniature
Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case–Control Study
Research Articles
FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors
Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer
A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing
NK Cell Education in Tumor Immune Surveillance: DNAM-1/KIR Receptor Ratios as Predictive Biomarkers for Solid Tumor Outcome
Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.